WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs 2019

ATC codeATC level name New DDD
P01BE02artemether0.28gR
P01BE03artesunate0.28gR
J05AR23atazanavir and ritonavir0.33)O
L04AA37baricitinib4mgO
R03DX10benralizumab0.54mgP
N05AX15cariprazine3mgO
J01DB11cefroxadine2.1gO
J01DD18cefteram0.4gO
J01DD63ceftriaxone and beta-lactamase inhibitor22)P
A05AA01chenodeoxycholic acid1gO
L04AA40cladribine0.34mgO
A07AA10colistin9MUO
J01MA23delafloxacin0.9gO
J01MA23delafloxacin0.6gP
J04AK06delamanid0.2gO
G04BD13desfesoterodine3.5mgO
C01CA27droxidopa1gO
D11AH05dupilumab21.4mgP
A07DA06eluxadoline0.2gO
B02BX06emicizumab15mgP
J05AX17enisamium iodide1.5gO
A10BK04ertugliflozin10mgO
G03CA03estradiol1.53mgTD spray
J01DI03faropenem0.75gO
G03GA10follitropin delta12mcgP
J01MA19garenoxacin0.4gO
J01MA15gemifloxacin0.32gO
L04AC16guselkumab1.79mgP
A10AE54insulin glargine and lixisenatide401)P
A07AA08kanamycin3gO
J05AX18letermovir0.48gO,P
J01MA07lomefloxacin0.4gO
R03DA12mepyramine theophyllinacetate0.6gO
J01FA03midecamycin1.2gO
G02AD06misoprostol0.2mgO
A06AH05naldemedine0.2mgO
M09AX07nusinersen0.1mgP
L04AA36ocrelizumab3.29mgP
V03AE09patiromer calcium8.4gO
J05AX21pentanedioic acid imidazolyl ethanamide 90mgO
P01BD51pyrimethamine, combinations75mg 4)P
R03DX08reslizumab7.1mgP
J05AC02rimantadine0.2gO
A04AD14rolapitant0.18gO
L04AC14sarilumab14.3mgP
P01AB07secnidazole2gO
J01DH06tebipenem pivoxil0.56gO
A16AX15telotristat0.75gO
H03AA05thyroid gland preparations0.1gO
J05AX19tilorone0.125gO
J01MA22tosufloxacin0.45gO
1) refers to insulin glargine
2) refers to ceftriaxone
3) refers to atazanavir
4) refers to pyrimethamine

Last updated: 2018-11-26